Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 14/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.54 |
| ▸ | NCOR2 | Q9Y618 | 5/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27659483 | 0.92 | FPR2 (0.56) | FPR2HDAC2HDAC1HDAC8HDAC3 | |
| SCHEMBL13288515 | 0.88 | HDAC2 (0.63) | HDAC2HDAC1HDAC8HDAC3HDAC10 | |
| SCHEMBL8271583 | 0.87 | HDAC2 (0.68) | HDAC2HDAC1HDAC8HDAC3HDAC10 | |
| SCHEMBL8270619 | 0.87 | HDAC8 (0.57) | FPR2HDAC2HDAC1HDAC8HDAC3 | |
| SCHEMBL8272312 | 0.87 | HDAC2 (0.64) | FPR2HDAC2HDAC1HDAC8HDAC3 | |
| SCHEMBL13288519 | 0.85 | HDAC1 (0.64) | HDAC2HDAC1HDAC8HDAC3HDAC10 | |
| SCHEMBL13288500 | 0.84 | HDAC2 (0.61) | FPR2HDAC2HDAC1HDAC8HDAC3 | |
| SCHEMBL8269734 | 0.83 | HDAC2 (0.57) | HDAC2HDAC1HDAC8HDAC3HDAC10 | |
| SCHEMBL13288499 | 0.82 | HDAC1 (0.64) | HDAC2HDAC1HDAC8HDAC3HDAC10 | |
| SCHEMBL8270608 | 0.82 | HDAC2 (0.58) | HDAC2HDAC1HDAC8HDAC3HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737184-B2 | Histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737184-B2 | Histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20080033015-A1 | Histone Deacetylase Inhibitors | MERCK SHARP & DOHME LLC | 2008-02-07 | — | — | US | disclosed |
| US-20080033015-A1 | Histone Deacetylase Inhibitors | MERCK SHARP & DOHME LLC | 2008-02-07 | — | — | US | disclosed |
| WO-2006017216-A1 | HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033015-A1 | Histone Deacetylase Inhibitors | HDAC1, HDAC5, HDAC9 | FPR2 2735/4885HDAC2 8/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.